Clorox names Gina Boswell to its board of directors

OAKLAND, Calif. - The Clorox Company (NYSE: CLX) has announced the appointment of Gina Boswell, CEO of Bath & Body Works, Inc., to its board of directors, a move set to take effect on May 19, 2025. Boswell, 62, brings a wealth of experience from her leadership roles in prominent consumer goods companies, including Unilever and Estée Lauder, and her service on various public company boards.

Linda Rendle, Clorox’s chair and CEO, expressed confidence in Boswell’s ability to contribute to the company’s strategic growth, citing her "exceptional consumer experience" and global expertise as key assets. The company, with a market capitalization of $17 billion and an impressive 48-year track record of consecutive dividend increases, maintains a moderate debt level while delivering a 45% gross profit margin. Boswell’s election will expand the Clorox board to 12 members.

The Clorox Company, known for its portfolio of household brands such as Brita, Burt’s Bees, and Pine-Sol, has been headquartered in Oakland since 1913 and has a history of integrating Environmental, Social, and Governance (ESG) factors into its business practices. The company recently achieved recognition as the No. 1 Most Sustainable Company on Barron’s list for the third year in a row.

This appointment is based on a press release statement and provides investors with the latest development in Clorox’s board composition.

In other recent news, Clorox’s fiscal third-quarter earnings report revealed a miss on both revenue and earnings per share, prompting several financial firms to adjust their outlooks on the company’s stock. Jefferies lowered Clorox’s price target to $167 from $177 but maintained a Buy rating, citing challenges in the Home and Personal Care sector affecting the company’s performance. Similarly, Wells Fargo reduced their price target from $145 to $142, keeping an Equal Weight rating, while expressing caution about the company’s valuation amid declining consumer demand.

Raymond James maintained a Market Perform rating after Clorox’s EPS of $1.45 fell short of their estimate of $1.57. The company’s organic sales declined by 2%, contrasting with expectations of flat growth. Despite these setbacks, Clorox’s gross margin improved to 44.6%, surpassing expectations. JPMorgan also adjusted their price target to $144 from $151, citing a reduced sales outlook due to decelerating consumer demand and retailer destocking.

Evercore ISI cut Clorox’s price target to $140 from $150, maintaining an Underperform rating following the earnings shortfall. The Household segment experienced a significant decline, attributed to retailer destocking and unfavorable weather conditions. The analysts’ reports highlight ongoing challenges for Clorox in achieving sustainable top-line growth amid competitive pressures and market dynamics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.